查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649467

皮下给药市场：预测（2025-2030）

Subcutaneous Drug Delivery Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

皮下给药市场规模在 2025 年预计为 417.04 亿美元，预计到 2030 年将达到 565.03 亿美元，预测期内的复合年增长率为 6.26%。

皮下给药装置市场正在经历快速成长，主要受对先进微创解决方案的需求不断增长的推动。心血管疾病（CVD）和糖尿病等慢性疾病的发生率不断上升，加上生物药品开发的进步，正在改变医疗保健模式。

皮下给药市场驱动因素：

  • 药物设备系统在慢性病管理中的作用：气喘、多发性硬化症、心血管疾病和糖尿病等慢性病的管理是全球面临的重大健康挑战。例如，美国气喘和过敏基金会报告称，气喘影响着美国约 2800 万人，即大约每 12 人中就有 1 人。预填充式注射器和自动注射器等药物装置输送系统的采用是改善病患治疗效果和减轻医疗负担的重大进步。这些系统透过提供精确的剂量增加了患者的便利性，从而减少了因临床程序而去医院就诊的需要并解决了慢性病管理中的关键差距。

糖尿病患者数量的不断增加促使企业进行创新并采取策略性倡议，引进先进的皮下给药装置。预填充式注射器，尤其是胰岛素自动注射器，已成为一种创新的解决方案，使患者能够以最小的不适感有效地自行给药。根据IDF糖尿病地图集（2021年），20-79岁的成年人中有10.5％患有糖尿病，近一半的人并未意识到自己的症状。预测表明，到 2045 年，每八名成年人中就有一人患有糖尿病，人数将增加 46%，达到 7.83 亿。其中超过 90% 的病例为第 2 型糖尿病，社会经济、人口、环境和遗传因素都是导致此疾病的因素。

皮下给药市场的地理展望：

  • 预计北美将占据主要市场占有率：预计在预测期内北美将主导皮下药物输送装置市场。这一增长得益于发达的医疗保健基础设施、对创新的重视以及先进的技术力。北美医疗保健产业受益于高度发展的医疗设施和广泛使用的先进药物传输技术。

此外，对本地研发的大量投资正在推动设备的持续创新。糖尿病、自体免疫疾病和心血管疾病等慢性病的高盛行率是北美市场的主要驱动力。根据美国美国有约2,970万人（约占总人口的8.9%）患有糖尿病。用于皮下给药的设备，例如胰岛素笔、自动注射器和穿戴式註射器，正在成为慢性病的重要管理工具。这些设备为需要持续照护的患者提供了更大的便利性、准确性和易用性。摘要，皮下给药市场预计将出现显着增长，这归因于一些因素，这些因素强化了这一不断扩大的市场格局，例如对慢性病管理创新解决方案的需求不断增长、糖尿病和心血管疾病等疾病的患病率不断上升、药物设备技术的进步、支持性法规环境、以及重大的地理发展，尤其是在北美。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 适合广泛的用户：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 收益成长和预测包括国家在内的细分市场和地区分析
  • 公司概况（策略、产品、财务、主要发展等）

皮下给药市场细分如下：

依产品类型：

  • 预填充式注射器
  • 笔型注射器
  • 自动注射器
  • 穿戴式註射器
  • 无针注射器

按用途分类：

  • 糖尿病
  • 生育能力
  • 肿瘤学
  • 其他的

按最终用户

  • 医院和诊所
  • 居家医疗
  • 门诊手术中心

按地区：

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • 以色列
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 其他的

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

5. 皮下给药市场（依产品类型）

  • 介绍
  • 预填充式注射器
  • 笔型注射器
  • 自动注射器
  • 穿戴式註射器
  • 无针注射器

第六章 皮下给药市场（依应用）

  • 介绍
  • 糖尿病
  • 生育能力
  • 肿瘤学
  • 其他的

7. 皮下给药市场（依最终用户划分）

  • 介绍
  • 医院和诊所
  • 居家医疗
  • 门诊手术中心

8. 皮下给药市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Gerresheimer AG
  • Ypsomed AG
  • Medtronic Plc
  • Sanofi
  • Novo Nordisk
  • Becton, Dickinson and Company
  • Elcam Medical Group
  • Unilife Corporation
  • Insulet Corporation
  • Eli Lilly and Company
简介目录
Product Code: KSI061617243

The subcutaneous drug delivery market is estimated at USD41.704 billion in 2025 and is anticipated to grow at a CAGR of 6.26% during the forecast period and reach USD56.503 billion in 2030.

The market for subcutaneous drug delivery devices is experiencing rapid growth, primarily fueled by the increasing demand for advanced minimally invasive solutions. The rising prevalence of chronic conditions such as cardiovascular disease (CVD) and diabetes, along with advancements in biological drug development, is transforming the healthcare landscape.

Drivers of the Subcutaneous Drug Delivery Market:

  • Role of Drug-Device Systems in Chronic Disease Management: The management of chronic diseases such as asthma, multiple sclerosis, cardiovascular conditions, and diabetes presents significant global health challenges. For example, the Asthma and Allergy Foundation of America reports that asthma affects nearly 28 million people in the United States, or about 1 in 12 individuals. The adoption of drug-device delivery systems, including prefilled syringes and autoinjectors, represents a significant advancement in improving patient outcomes and reducing healthcare burdens. These systems enhance patient convenience by delivering accurate doses, thereby decreasing the need for hospital visits for clinical procedures and addressing critical gaps in chronic disease management.

The increasing diabetes patient population has prompted companies to innovate and implement strategic initiatives to introduce advanced subcutaneous drug delivery devices. Prefilled syringes, particularly insulin autoinjectors, have emerged as transformative solutions that allow patients to self-administer medications efficiently and with minimal discomfort. According to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 years have diabetes, with nearly half unaware of their condition. Projections indicate that by 2045, 1 in 8 adults will be living with diabetes, marking a 46% increase to an estimated 783 million individuals. Over 90% of these cases are type 2 diabetes, driven by socio-economic, demographic, environmental, and genetic factors.

Geographical Outlook of the Subcutaneous Drug Delivery Market:

  • North America Expected to Hold a Major Market Share: North America is anticipated to dominate the subcutaneous drug delivery devices market during the forecast period. This growth is attributed to a well-developed healthcare infrastructure, a strong emphasis on innovation, and advanced technological capabilities within the region. The healthcare sector in North America benefits from highly developed medical facilities that provide widespread access to advanced drug delivery technologies.

Additionally, significant investments in regional research and development are driving continuous innovation in subcutaneous drug delivery devices. The high prevalence of chronic conditions such as diabetes, autoimmune disorders, and cardiovascular diseases serves as a primary market driver in North America. According to estimates from the Centers for Disease Control and Prevention (CDC), approximately 29.7 million people in the United States-about 8.9% of the population-had diabetes in 2022. This underscores the importance of effective and accessible treatment options.Devices designed for subcutaneous drug delivery-such as insulin pens, auto-injectors, and wearable injectors-are becoming essential management tools for chronic conditions. These devices offer greater convenience, precision, and user-friendliness for patients requiring ongoing treatments. With an aging population and an increasing prevalence of chronic diseases, the market for these devices is expected to expand further, solidifying North America's position as a leader in the global subcutaneous drug delivery market.In summary, the subcutaneous drug delivery market is poised for substantial growth driven by rising demand for innovative solutions in chronic disease management, increasing prevalence of conditions like diabetes and cardiovascular diseases, advancements in drug-device technology, supportive regulatory environments, and significant geographical developments-particularly within North America-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Subcutaneous Drug Delivery Market has been segmented as following:

By Product Type:

  • Prefilled syringes
  • Pen injector
  • Autoinjectors
  • Wearable injectors
  • Needle-free Injectors

By Application:

  • Diabetes
  • Fertility
  • Oncology
  • Others

By End-Users:

  • Hospitals and Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers

By Geography:

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SUBCUTANEOUS DRUG DELIVERY MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Prefilled syringes
  • 5.3. Pen injector
  • 5.4. Autoinjectors
  • 5.5. Wearable injectors
  • 5.6. Needle-free Injectors

6. SUBCUTANEOUS DRUG DELIVERY MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Fertility
  • 6.4. Oncology
  • 6.5. Others

7. SUBCUTANEOUS DRUG DELIVERY MARKET BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Homecare Settings
  • 7.4. Ambulatory Surgical Centers

8. SUBCUTANEOUS DRUG DELIVERY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Gerresheimer AG
  • 10.2. Ypsomed AG
  • 10.3. Medtronic Plc
  • 10.4. Sanofi
  • 10.5. Novo Nordisk
  • 10.6. Becton, Dickinson and Company
  • 10.7. Elcam Medical Group
  • 10.8. Unilife Corporation
  • 10.9. Insulet Corporation
  • 10.10. Eli Lilly and Company